papaji schreef op 8 maart 2016 18:58:
[...]
In het vorige jaarrapport (14) was het volgende opgenomen voor 2015:
OUTLOOK
- Following the Ruconest launch in the US, the Company continues to invest in purification of sufficient quantities of Ruconest, out of the existing bulk inventory buffers (frozen milk).
- The Company also expects to make investments in the continuing Phase II clinical trial for prophylaxis of HAE, which is a 50/50 cost sharing project with US partner Salix.
- In addition the (early) development of new pipeline projects driven by the French Research Group and the Bostonbased NPD group, will require new investments.
- Direct commercialisation in Austria, Germany and the Netherlands will require investments.
- The Company continues to support its partners to market its products in the various territories in order to grow sales as it believes that Ruconest is a valuable addition to the therapeutic options available to HAE patients
SUMMARY OF GOALS FOR 2015
- Achievement of (internal) market share/sales targets for Ruconest, in the US by Salix Pharmaceuticals.
- Achievement of (internal) market share/sales targets for Ruconest in Europe and other territories by our partners Sobi and MegaPharm and by direct commercialisation in Austria, Germany and the Netherlands.
- Completion of the Phase II randomised clinical trial of Ruconest for the prophylaxis of HAE.
- Prioritisation of new development projects and execution of the new Products’ early development plans.
- Develop the Company’s visibility amongst investors and other market participants (both buy- and sell-side analysts and financial press and trade press journalists).
- No guidance on total revenues from sales is provided for the financial results in 2015.
Tja, dat stelde natuurlijk helemaal niks voor, en ik verwacht nu dan ook wel een ander, voornamelijk positief riedeltje met misschien zelfs een sales forecast???